Clinical Trial Update: Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a personalized high-dose aflibercept (8 mg) regimen for treatment-naive polypoidal choroidal vasculopathy; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• Aflibercept (high-dose 8 mg) (aflibercept)

Snippet

Sponsor: Yeungnam University College of Medicine | Conditions: Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Status: RECRUITING